Fish pathogen

Toxin from salmonid fish has potential to treat cancer

Pathogenic bacteria develop killer machines that work very specifically and highly efficiently. Scientists from the University of Freiburg have solved the molecular mechanism of a fish toxin that could be used in the future as a medication to treat cancer.

Rainbow trout
Rainbow trout
Source: Fotolia/Nikolay Pozdeyev

The Yersinia species of pathogens can cause the bubonic plague and serious gastrointestinal infections in humans. The pharmacologist Dr. Thomas Jank and his fellow researchers in the research group led by Prof. Dr. Dr. Klaus Aktories at the University of Freiburg studied a pathogen of the Yersinia family (Yersinia ruckeri). This pathogen causes redmouth disease in Salmonidae, which includes salmon and trout, resulting in large financial losses in the fish industry. The research group was able to identify a toxin injection machine in the Y. ruckeri genome. The structure of this machine resembles that of viruses that normally attack bacteria. The group demonstrated that the toxin Afp18 in this injection machine is an enzyme that deactivates the switch protein RhoA. RhoA is responsible for many vital processes in the cells of humans and fish. For example, it controls the building up and breaking down of actin filaments. These filaments are not only necessary for cell division, but also for the spreading of tumour metastases in the body.

In close collaboration with the developmental biologist Prof. Dr. Wolfgang Driever, also from the University of Freiburg, the research group injected the toxin Afp18 into zebra fish embryos. The result was that cell division was blocked, and the fish embryos did not develop. The toxin caused the actin filaments in the fish cells to collapse. This is because the Afp18 attaches a sugar molecule, an N-acetylglucosamine, onto the amino acid tyrosine in RhoA. According to the scientists, this is a very unusual reaction in nature. The team was able to shed light on this mechanism at the atomic level through the X-ray analysis of Afp18-modified RhoA crystals. For this, they collaborated with Prof. Dr. Daan von Aalten from the University of Dundee, Scotland. Rho-regulatory proteins are involved in the growth of cancer, especially metastasis. For this reason, the researchers from the University of Freiburg believe that this fish toxin has great therapeutic potential in cancer treatment.


Original publication:
Thomas Jank*, Stephanie Eckerle*, Marcus Steinemann*, Christoph Trillhaase, Marianne Schimpl, Sebastian Wiese, Daan M.F. van Aalten, Wolfgang Driever & Klaus Aktories, “Tyrosine glycosylation of Rho by Yersinia toxin impairs blastomere cell behaviour in zebrafish embryos.” Nature Communications 2015.
*Authors are equally involved.


Source: University of Freiburg

29.07.2015

Related articles

Photo

News • Tackling bacterial infections

Personalised phage therapy as alternative to antibiotics

The current rise in antibiotic resistance is once again sparking interest in phage therapy. Now, scientists developed a new tool that recommends the best possible phage cocktail for a given patient.

Photo

News • MTX in the mix

Researchers develop novel therapy for vancomycin-resistant infections

Researchers from the US, Singapore and Geneva have developed a novel combination therapy using an anticancer agent for treating vancomycin-resistant Enterococcus faecalis (VRE).

Photo

News • Coronavirus

COVID-19: Enzyme blocks immune response to infection

Researchers from Cleveland Clinic’s Florida Research and Innovation Center (FRIC) have identified a potential new target for anti-COVID-19 therapies.

Related products

Subscribe to Newsletter